EUVIMEDEUVIMED entdecken
Crossref

An Allogeneic PBMC–Organoid Co-culture Platform for Evaluating Immunotherapy Efficacy and T-Cell-Mediated Antitumor Immunity

Liangshan Hu, Yadong Liu, You Chen, Jiajia Ma, Jing Li, Jie Liu iD, Donglin Cao

ACS Applied Bio Materials · 10.11.2026

DOI: 10.1021/acsabm.6c01270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 10.11.2026. Verfasst von Liangshan Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Guangdong Second Provincial General Hospital of Jinan University, The Second School of Clinical Medicine, Southern Medical University …. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Technology Research Program of Guangzhou City, Science Foundation of Guangdong Second Provincial General Hospital, China University Industry-University-Research Innovation Fund ? Jiuqiang Clinical Laboratory Medicine Special Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional 2D cell lines and mouse xenograft models have limitations in recapitulating the complexity of the tumor microenvironment (TME) and dynamic interactions between tumor and immune cells, creating an urgent need for models to evaluate immunotherapies. Patient-derived organoids (PDOs), which retain key features of original tumors, offer a platform for dissecting the TME when co-cultured with peripheral blood mononuclear cells (PBMCs). However, challenges such as inter-batch variability of PBMCs and difficulties in autologous PBMC acquisition hinder their clinical translation. This study established four stably passaged colorectal cancer organoid models and developed an allogeneic PBMC–organoid co-culture platform to investigate the immune activation and cytotoxic potential of allogeneic PBMCs. Results showed that vacuolated-structured organoids are associated with the increased proportion of CD8+ T cells in PBMCs within the co-culture system. PBMCs exhibited stronger cytotoxicity against microsatellite-stable (MSS) organoids with low PD-L1 expression, while the anti-PD-1 antibody Keytruda significantly enhanced their antitumor effects on high PD-L1-expressing organoids. The allogeneic co-culture model developed here overcomes the limitations of autologous PBMC acquisition, providing an efficient and versatile proof-of-concept platform for pre-clinical screening of immunotherapeutic drugs. Distinct from prior allogeneic co-culture systems that rely on healthy donor immune cells, our platform uniquely integrates patient-derived allogeneic PBMCs with tumor organoids, providing preliminary proof-of-concept evidence that tumor-intrinsic features may influence immunotherapy responses based on tumor-intrinsic features while preserving the pathological relevance of cancer patient immune profiles.

Schlagwörter

Stichwörter der Autor:innen

allogeneic PBMCsco-culture platformcolorectal cancer organoidsimmunotherapytumor microenvironment

Autor:innen und Institutionen

  • The Affiliated Guangdong Second Provincial General Hospital of Jinan University, The Second School of Clinical Medicine, Southern Medical University , Guangzhou510317, China.
  • Guangdong Second Provincial General Hospital, Postdoctoral Research Station of Biomedical Engineering Jinan University, Guangzhou510632, China.
  • School of Biomedical Engineering, Shenzhen Campus of Sun Yat-Sen University, NO.66, Gongchang Road, ShenzhenGuangdong518107, China.
  • NMPA Center for Innovation and Research in Regulatory Science, School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, Shenzhen518107, China.

ORCID-Profile: Jie Liu

Förderung

  • Technology Research Program of Guangzhou City
  • Science Foundation of Guangdong Second Provincial General Hospital
  • China University Industry-University-Research Innovation Fund ? Jiuqiang Clinical Laboratory Medicine Special Program
  • Ministry of Education Industry-University Collaborative Education Project
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Hu, L., Liu, Y., Chen, Y., Ma, J., Li, J., Liu, J., & Cao, D. (2026). An Allogeneic PBMC–Organoid Co-culture Platform for Evaluating Immunotherapy Efficacy and T-Cell-Mediated Antitumor Immunity. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.6c01270

Vancouver

Hu L, Liu Y, Chen Y, Ma J, Li J, Liu J, et al. An Allogeneic PBMC–Organoid Co-culture Platform for Evaluating Immunotherapy Efficacy and T-Cell-Mediated Antitumor Immunity. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.6c01270

BibTeX
@article{Hu2026,
  author = {Hu, Liangshan and Liu, Yadong and Chen, You and Ma, Jiajia and Li, Jing and Liu, Jie and Cao, Donglin},
  title = {An Allogeneic PBMC–Organoid Co-culture Platform for Evaluating Immunotherapy Efficacy and T-Cell-Mediated Antitumor Immunity},
  journal = {ACS Applied Bio Materials},
  year = {2026},
  doi = {10.1021/acsabm.6c01270}
}
Kostenlos starten →